[Congress of the European Association of Urology (EAU) and the American Urological Association (AUA) 2005: The present status of 5-alpha reductase inhibitors]

[Article in French]

Affiliations

Review

[Article in French]

F Desgrandchamps. Ann Urol (Paris). 2005 Aug.

. 2005 Aug:39 Suppl 2:S18-28.

doi: 10.1016/s0003-4401(05)80003-8.

¹ Service d'urologie, Hôpital Saint-Louis, 1, avenue Claude Vellefaux, 75010 Paris, France. francois.desgrandchamps@sls.aphp.fr

No abstract available

Similar articles

[Dual 5-alpha reductase inhibitors in BPH (benign prostatic hyperplasia). Already after 1 month prostate shrinks].
[No authors listed] [No authors listed] MMW Fortschr Med. 2003 Feb 27;145(9):54. MMW Fortschr Med. 2003. PMID: 12666533 German. No abstract available.
Benign prostatic hyperplasia.
Barry MJ, Roehrborn CG. Barry MJ, et al. BMJ. 2001 Nov 3;323(7320):1042-6. doi: 10.1136/bmj.323.7320.1042. BMJ. 2001. PMID: 11691764 Free PMC article. Review. No abstract available.
Benign prostatic hyperplasia.
Webber R. Webber R. Clin Evid. 2006 Jun;(15):1213-26. Clin Evid. 2006. PMID: 16973049 Review. No abstract available.
Benign prostatic hyperplasia.
Webber R. Webber R. Clin Evid. 2005 Dec;(14):1076-91. Clin Evid. 2005. Update in: Clin Evid. 2006 Jun;(15):1213-26. PMID: 16620448 Updated. Review. No abstract available.
EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.
Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N'dow J, Nordling J, de la Rosette JJ; European Association of Urology. Oelke M, et al. Eur Urol. 2013 Jul;64(1):118-40. doi: 10.1016/j.eururo.2013.03.004. Epub 2013 Mar 13. Eur Urol. 2013. PMID: 23541338 Review.